Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC
Holding BNTC?
Track your performance easily
BNTC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.69 - $12.89
Previous Close$10.49
Volume9.62K
Average Volume (3M)32.67K
Market Cap
$238.20M
Enterprise Value$243.89M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$354.00K
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Feb 17, 2025EPS Estimate
-$1.02Last Dividend Ex-Date
Jun 01, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-5.28
Shares Outstanding23,216,425
10 Day Avg. Volume39,652
30 Day Avg. Volume32,673
Standard Deviation0.26
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.86
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-12.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.52K
Enterprise Value/Gross Profit3.25K
Enterprise Value/Ebitda-11.57
Forecast
1Y Price Target
$24.00Price Target Upside133.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Benitec Biopharma News
PremiumCompany Announcements
Benitec Biopharma Awards Bonuses to Key Executives
PremiumCompany Announcements
Benitec Biopharma Reports Promising Results for BB-301 Trial
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe price target for the stock has been increased to $20 from $13, reflecting early evidence of disease reversal.
Market OpportunityNo treatments have been approved for OPMD, highlighting a significant unmet need and opportunity for BB-301 as the first of its kind.
Product PotentialBB-301 offers meaningful clinical benefit at this low dose, potentially providing a significant improvement in patient-reported outcomes for those with limited treatment options for OPMD.
Bears Say
Clinical TrialsDelays in converting patients from the natural history run-in study to the Phase 1/2 trial could push out initial timelines.
Price TargetA placebo-controlled pivotal trial and/or signs of benefit eroding over time could imply an $11 downside to the price target.
Research And DevelopmentR&D spending of $3.5mm was above consensus expectations of $2.6mm, indicating higher costs than anticipated.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTC FAQ
What was Benitec Biopharma Ltd’s price range in the past 12 months?
Benitec Biopharma Ltd lowest stock price was $2.69 and its highest was $12.89 in the past 12 months.
What is Benitec Biopharma Ltd’s market cap?
Currently, no data Available
When is Benitec Biopharma Ltd’s upcoming earnings report date?
Benitec Biopharma Ltd’s upcoming earnings report date is Feb 17, 2025 which is in 84 days.
How were Benitec Biopharma Ltd’s earnings last quarter?
Benitec Biopharma Ltd released its earnings results on Nov 14, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.55 by $0.07.
Is Benitec Biopharma Ltd overvalued?
According to Wall Street analysts Benitec Biopharma Ltd’s price is currently Undervalued.
Does Benitec Biopharma Ltd pay dividends?
Benitec Biopharma Ltd pays a Notavailable dividend of $0.51 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma Ltd dividends here
What is Benitec Biopharma Ltd’s EPS estimate?
Benitec Biopharma Ltd’s EPS estimate is -$1.02.
How many shares outstanding does Benitec Biopharma Ltd have?
Benitec Biopharma Ltd has 23,216,425 shares outstanding.
What happened to Benitec Biopharma Ltd’s price movement after its last earnings report?
Benitec Biopharma Ltd reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.55. Following the earnings report the stock price went up 2.692%.
Which hedge fund is a major shareholder of Benitec Biopharma Ltd?
Currently, no hedge funds are holding shares in BNTC
---
Benitec Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (133.92% Upside)
$24.00 (133.92% Upside)
Blogger Sentiment
Bullish
BNTC Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $21.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 27.1%
Last 30 Days ▲ 27.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
215.96%
12-Months-Change
Fundamentals
Return on Equity
-48.23%
Trailing 12-Months
Asset Growth
154.22%
Trailing 12-Months
Company Description
Benitec Biopharma Ltd
Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in North Sydney, Australia.
---
BNTC Stock 12 Month Forecast
Average Price Target
$24.00
▲(133.92% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering BNTC
1 Year
1 Year Success Rate
13/16 ratings generated profit
1 Year Average Return
+71.04%
reiterated a buy rating 8 days ago
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +71.04% per trade.
---